Biotech Weekly Recap
Week covered: Dec 8–12, 2025 (Mon–Fri) • Primary sources linked inside each card
Approvals / label changes
Clinical readouts
Setbacks
Language switch (no script).
Executive Summary
This week was strongly event-driven: multiple FDA actions (including a first-in-class gene therapy), two oral approvals in gonorrhea, and several high-visibility clinical readouts (metabolic/obesity and rare disease). Below you’ll find the key items, compact but with real numbers and direct primary links.
Informational only. No investment advice. Verify details in the linked primary documents.
FDA approvals / label expansions (high-impact items)
Omisirge (omidubicel-onlv) — Gamida Cell
Indication: Severe aplastic anemia (HSCT option when no compatible donor).
- FDA described early and sustained neutrophil recovery in an ongoing study.
- Approval supports adult + pediatric use (per FDA label/announcement).
Waskyra (etuvetidigene autotemcel) — Fondazione Telethon ETS
Indication: Wiskott-Aldrich syndrome (WAS).
- FDA: evidence across studies + expanded access totaling 27 patients.
- FDA summary highlighted reduction in severe infections and bleeding events post-treatment.
Blujepa (gepotidacin) — GSK
Indication: Uncomplicated urogenital gonorrhea (specific limitation noted by FDA).
- FDA press announcement lists it as an oral option for selected patients.
- FDA summarized comparative cure-rate performance in its announcement.
Nuzolvence (zoliflodacin) — Innoviva Specialty Therapeutics + GARDP
Indication: Uncomplicated urogenital gonorrhea (granules dissolved in water).
- FDA: Phase 3 trial enrolled 930 patients; comparable effectiveness summarized in the FDA announcement.
- Important category: new oral options in the context of antimicrobial resistance.
Akeega (niraparib + abiraterone + prednisone) — Janssen
Indication: BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).
- FDA: efficacy evaluated in AMPLITUDE (NCT04497844), 696 patients.
- FDA includes rPFS details and labeling specifics in its approval notification.
ORLADEYO oral pellets (berotralstat) — BioCryst
Indication: HAE prophylaxis in children 2 to <12 years (new formulation).
- Pellet formulation supports easier administration in younger patients.
- Company statement references APeX-P support and safety summary.
Clinical trial readouts (completed / topline updates)
Structure Therapeutics — aleniglipron (ACCESS / ACCESS II)
- Company release highlighted placebo-adjusted weight-loss figures at 36 weeks and AE-related discontinuation metrics.
- Obesity/overweight population; numbers-centered story (efficacy + tolerability).
Dyne Therapeutics — z-rostudirsen (DELIVER REC)
- REC met primary endpoint: muscle content–adjusted dystrophin expression reported by the company.
- Release included functional measures and longer-term context.
Ascletis — ASC30 (13-week U.S. Phase II)
- Company release reported placebo-adjusted weight loss at 13 weeks and dose-dependence.
- Also reported cardiometabolic marker changes (per release).
Rezolute — ersodetug (sunRIZE)
- Company announced the study did not meet the primary or key secondary endpoint.
- High placebo response was a major narrative point in the release.
Pattern (non-advisory): obesity/metabolic readouts keep being judged mainly on hard numbers (weight loss, discontinuations, tolerability), while rare-disease pivotal programs can turn on endpoint selection and placebo response.
Tools & Partners
Resources
Affiliate note: some links may be affiliate/referral links at no extra cost to you. This supports the site.
Support the project with a donation:
PayPal Donate
Legal: Disclaimer • Terms & Privacy
Authors: Merlintrader and Jane
In every report we share things as we personally interpret them, based on raw data from official filings, company communications, and primary verified sources where available. We are not professional analysts. Mistakes can happen; if you spot something off, tell us and we’ll correct it.
Biotech Catalyst Calendar
Track upcoming biotech catalysts in one place: merlintrader.com/calendario-catalyst
Riepilogo Esecutivo
Settimana molto “event-driven”: diverse azioni FDA (inclusa una gene therapy first-in-class), due approvazioni orali nella gonorrea, e readout clinici ad alta visibilità (metabolico/obesità e rare disease). Sotto trovi i punti chiave con numeri essenziali e link primari.
Solo informazione. Nessun consiglio. Verifica i dettagli nei documenti ufficiali linkati.
Approvazioni / estensioni FDA (eventi ad alto impatto)
Omisirge (omidubicel-onlv) — Gamida Cell
Indicazione: Severe aplastic anemia (opzione HSCT quando non c’è donatore compatibile).
- FDA: enfasi su recupero neutrofilico precoce e sostenuto nello studio in corso.
- Supporto a utilizzo adulti + pediatrico secondo label/annuncio FDA.
Waskyra (etuvetidigene autotemcel) — Fondazione Telethon ETS
Indicazione: Wiskott-Aldrich syndrome (WAS).
- FDA: evidenza da studi + expanded access (totale 27 pazienti).
- Nel riassunto FDA: riduzione infezioni severe e sanguinamenti post-trattamento.
Blujepa (gepotidacin) — GSK
Indicazione: Gonorrea urogenitale non complicata (limitazione specifica indicata da FDA).
- FDA: opzione orale per pazienti selezionati.
- FDA: include un riassunto comparativo sull’efficacia nel comunicato.
Nuzolvence (zoliflodacin) — Innoviva Specialty Therapeutics + GARDP
Indicazione: Gonorrea urogenitale non complicata (granuli da sciogliere in acqua).
- FDA: Phase 3 con 930 pazienti; nel comunicato FDA viene riassunta l’efficacia comparabile.
- Tema chiave: nuove opzioni orali e resistenze antibiotiche.
Akeega (niraparib + abiraterone + prednisone) — Janssen
Indicazione: mCSPC BRCA2-mutato.
- FDA: efficacia valutata in AMPLITUDE (NCT04497844), 696 pazienti.
- FDA: dettagli su rPFS e label nella notifica ufficiale.
ORLADEYO oral pellets (berotralstat) — BioCryst
Indicazione: Profilassi HAE 2–<12 anni (nuova formulazione).
- Formulazione pellets: facilità di somministrazione nei più piccoli.
- Comunicato: riferimento a supporto APeX-P e sintesi sicurezza.
Readout clinici (completati / topline)
Structure Therapeutics — aleniglipron (ACCESS / ACCESS II)
- Comunicato: focus su peso placebo-adjusted e metrica discontinuation legata a eventi avversi.
- Tipico “numbers-first”: efficacia + tollerabilità.
Dyne — z-rostudirsen (DELIVER REC)
- Comunicato: endpoint primario centrato e contesto funzionale/long-term.
- Rare disease: narrativa su biomarker + funzione + durata.
Ascletis — ASC30 (Phase II USA 13 settimane)
- Comunicato: peso placebo-adjusted e dose-dependence.
- Nel release: anche marker cardiometabolici (colesterolo, pressione, ecc.).
Rezolute — ersodetug (sunRIZE)
- Comunicato: studio non positivo su endpoint primario e key secondary.
- Narrativa chiave: risposta placebo elevata e interpretazione risultati.
Pattern (non operativo): nel metabolico/obesità conta il binomio “peso + tollerabilità”; nelle rare disease late-stage contano tantissimo endpoint e placebo response.
Tools & Partners
Risorse
Nota affiliate: alcuni link possono essere referral/affiliate senza costi extra. Serve a supportare il sito.
Supporta il progetto con una donazione:
PayPal Donate
Legale: Disclaimer • Termini & Privacy
Authors: Merlintrader and Jane
In ogni report condividiamo come interpretiamo i dati, basandoci su comunicazioni ufficiali e fonti primarie verificabili. Non siamo analisti professionisti. Errori possono capitare: se noti qualcosa di sbagliato, scrivicelo e lo correggiamo.
Biotech Catalyst Calendar
Calendario catalyst in un’unica pagina: merlintrader.com/calendario-catalyst